What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015

05-Aug-2011 | News-Press Release

The future of the pharmaceutical market will be determined by biologics - drugs produced by natural organisms or recombinant techniques consisting of proteins and other products derived from living organisms for the treatment or management of diseases or injuries. What are the products that lead the market now and what can we expect to see in the coming years?

This Kalorama Information report, What's Next in Biologics? represents our latest research into the market for non-vaccine biological drugs and the companies who compete in the market. The following are among the data points in this report:
• Biopharmaceutical Pipeline for Significant Companies
• Market Size of Biopharmaceuticals
• Monoclonal Antibodies (mAbs)
• Recombinant Hormones and Proteins (rDNA)
• Interferons and
• Other Biologics Industry
• Biopharmaceutical Market Forecast to 2015
• Products in Development: New Compound vs. Additional Indications
• Competitor Market Shares for Biopharmaceuticals
• Autoimmune, Cancer, Cardiovascular and Hormone Treatments Market Sizes and Competitor Shares
• Drug Development Cost Progression
• Leading Biotech Therapies by 2010 Revenues
• Population and Healthcare Spending Trends
• Select Biotechnology Drugs Approved for Marketing

Browse All: Biotechnology Market Research

The biologics industry encompasses a wide range of products including monoclonal antibodies, blood products, vaccines, and some diagnostics and devices. For the purpose of this study, Kalorama Information has focuses on those biologics that are used in conjunction with or as a replacement to traditional pharmaceutical treatment. For example, treatments for cancer, growth disorders, autoimmune diseases and blood disorders. This study excludes products such as vaccines—including prophylactic vaccines—which are covered in-depth in separate Kalorama studies. The following is among the qualitative analysis found in this report:
• The Role Government Incentives Will Play in the Future Biotech Market
• Pharmaceutical Regulatory Exclusivity
• Biosimilars: Where They Stand and What We Can Expect
• The Largest Areas of Research for Biopharmaceuticals
• Improvements in the Next Generation of Biologics
• The Impact of Aging Populations on Biotechnology Market Development
• Health Care Reform: What it Means
• Recent Mergers, Acquisitions, and Collaborations
• Contributors to R&D Success
• Targeted Cancer Therapy
• Genome Sequencing for Personalized Healthcare
• The Role of Contract Research Organizations

In the traditional pharmaceutical market, the pipeline is struggling to produce strong therapies and the growing number of drugs losing patent protection will more than offset revenues generated from new developments. For now, the biotechnology market is spared the impact of this setback as the path to generic or biosimilar development is more involved and the number of biotechnology drugs facing generic competition remains limited.

You can read table of contents for What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015

About Us:
ReportsnReports is an online library of over 100,000+ market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Follow us on Twitter:
Our Facebook Page:

7557 Rambler road,
Tel: +1-888-989-8004
Visit our Market Research Blog

Show HTML Embed Snippet

This release was submitted by a PRSafe user.
Any communication related to the content of this release should be sent to the release submitter.

Contact Info

From Name
From Email
From Company
Login to Submit Email

Author Info

Tag Cloud


More Releases


Add a Comment